Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.

Get Fee Email Updates

Has Pfizer Identified Compounds For Treatment Of Coronavirus?

By John F. Heerdink, Jr.

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products.  Reportedly, Drugmaker Pfizer has informed that it has identified certain antiviral compounds in development that has the potential to inhibit coronaviruses. The company said it is yet to involve a third party to verify the compounds and expects to have the results from the screening by the end of March. If the compounds are successful, Pfizer expects to start testing them by the end of the year. Pfizer Chief Scientific Officer Mikael Dolsten met with U.S. President Trump at the White House on Monday as one of the pharmaceutical executives.

To learn more about Pfizer (PFE) and to track its progress please visit the Vista Partners Pfizer Coverage Page


Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. 

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

feb2(12)

Post View Count : 570
(Read Original Story: Pfizer identified some antiviral compounds with potential as coronavirus treatments in Reuters)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us